Disappearing Colorectal Liver Metastases after Chemotherapy: Should we be Concerned?

Mark G. van Vledder, Mechteld C. de Jong, Timothy M. Pawlik, Richard D. Schulick, Luis A. Diaz, Michael A. Choti

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Background: With increasing efficacy of preoperative chemotherapy for colorectal cancer, more patients will present with one or more disappearing liver metastases (DLM) on preoperative cross-sectional imaging. Patients and Methods: A retrospective review was conducted evaluating the radiological response to preoperative chemotherapy for 168 patients undergoing surgical therapy for colorectal liver metastases at Johns Hopkins Hospital between 2000 and 2008. Results: Forty patients (23. 8%) had one or more DLM, accounting for a total of 127 lesions. In 22 patients (55%), all DLM sites were treated during surgery. Of the 17 patients with unidentified, untreated DLM, ten patients (59%) developed a local recurrence at the initial site, half of which also developed recurrences in other sites. While the intrahepatic recurrence rate was higher for patients with DLM left in situ (p = 0.04), the 1-, 3-, and 5-year overall survival rate was not significantly different for patients with DLM left in situ (93.8%, 63.5%, and 63.5%, respectively) when compared to patients with a radiological chemotherapy response in whom all original disease sites were surgically treated (92.3%, 70.8%, and 46.2%, respectively; p = 0.66). Conclusions: DLM were frequently observed in patients undergoing preoperative chemotherapy for liver metastases. Survival was comparable in patients with untreated DLM, in spite of high intrahepatic recurrence rates seen in these patients. Therefore, aggressive surgical therapy should be considered in patients with marked response to chemotherapy, even when all DLM sites cannot be identified.

Original languageEnglish (US)
Pages (from-to)1691-1700
Number of pages10
JournalJournal of Gastrointestinal Surgery
Volume14
Issue number11
DOIs
StatePublished - 2010

Fingerprint

Neoplasm Metastasis
Drug Therapy
Liver
Recurrence
Colorectal Neoplasms
Survival Rate
Survival
Therapeutics

Keywords

  • Chemotherapy
  • Colorectal liver metastases
  • Liver resection

ASJC Scopus subject areas

  • Surgery
  • Gastroenterology

Cite this

van Vledder, M. G., de Jong, M. C., Pawlik, T. M., Schulick, R. D., Diaz, L. A., & Choti, M. A. (2010). Disappearing Colorectal Liver Metastases after Chemotherapy: Should we be Concerned? Journal of Gastrointestinal Surgery, 14(11), 1691-1700. https://doi.org/10.1007/s11605-010-1348-y

Disappearing Colorectal Liver Metastases after Chemotherapy : Should we be Concerned? / van Vledder, Mark G.; de Jong, Mechteld C.; Pawlik, Timothy M.; Schulick, Richard D.; Diaz, Luis A.; Choti, Michael A.

In: Journal of Gastrointestinal Surgery, Vol. 14, No. 11, 2010, p. 1691-1700.

Research output: Contribution to journalArticle

van Vledder, MG, de Jong, MC, Pawlik, TM, Schulick, RD, Diaz, LA & Choti, MA 2010, 'Disappearing Colorectal Liver Metastases after Chemotherapy: Should we be Concerned?', Journal of Gastrointestinal Surgery, vol. 14, no. 11, pp. 1691-1700. https://doi.org/10.1007/s11605-010-1348-y
van Vledder, Mark G. ; de Jong, Mechteld C. ; Pawlik, Timothy M. ; Schulick, Richard D. ; Diaz, Luis A. ; Choti, Michael A. / Disappearing Colorectal Liver Metastases after Chemotherapy : Should we be Concerned?. In: Journal of Gastrointestinal Surgery. 2010 ; Vol. 14, No. 11. pp. 1691-1700.
@article{6c44e86d8a7945d2a06b101cf524cb16,
title = "Disappearing Colorectal Liver Metastases after Chemotherapy: Should we be Concerned?",
abstract = "Background: With increasing efficacy of preoperative chemotherapy for colorectal cancer, more patients will present with one or more disappearing liver metastases (DLM) on preoperative cross-sectional imaging. Patients and Methods: A retrospective review was conducted evaluating the radiological response to preoperative chemotherapy for 168 patients undergoing surgical therapy for colorectal liver metastases at Johns Hopkins Hospital between 2000 and 2008. Results: Forty patients (23. 8{\%}) had one or more DLM, accounting for a total of 127 lesions. In 22 patients (55{\%}), all DLM sites were treated during surgery. Of the 17 patients with unidentified, untreated DLM, ten patients (59{\%}) developed a local recurrence at the initial site, half of which also developed recurrences in other sites. While the intrahepatic recurrence rate was higher for patients with DLM left in situ (p = 0.04), the 1-, 3-, and 5-year overall survival rate was not significantly different for patients with DLM left in situ (93.8{\%}, 63.5{\%}, and 63.5{\%}, respectively) when compared to patients with a radiological chemotherapy response in whom all original disease sites were surgically treated (92.3{\%}, 70.8{\%}, and 46.2{\%}, respectively; p = 0.66). Conclusions: DLM were frequently observed in patients undergoing preoperative chemotherapy for liver metastases. Survival was comparable in patients with untreated DLM, in spite of high intrahepatic recurrence rates seen in these patients. Therefore, aggressive surgical therapy should be considered in patients with marked response to chemotherapy, even when all DLM sites cannot be identified.",
keywords = "Chemotherapy, Colorectal liver metastases, Liver resection",
author = "{van Vledder}, {Mark G.} and {de Jong}, {Mechteld C.} and Pawlik, {Timothy M.} and Schulick, {Richard D.} and Diaz, {Luis A.} and Choti, {Michael A.}",
year = "2010",
doi = "10.1007/s11605-010-1348-y",
language = "English (US)",
volume = "14",
pages = "1691--1700",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "11",

}

TY - JOUR

T1 - Disappearing Colorectal Liver Metastases after Chemotherapy

T2 - Should we be Concerned?

AU - van Vledder, Mark G.

AU - de Jong, Mechteld C.

AU - Pawlik, Timothy M.

AU - Schulick, Richard D.

AU - Diaz, Luis A.

AU - Choti, Michael A.

PY - 2010

Y1 - 2010

N2 - Background: With increasing efficacy of preoperative chemotherapy for colorectal cancer, more patients will present with one or more disappearing liver metastases (DLM) on preoperative cross-sectional imaging. Patients and Methods: A retrospective review was conducted evaluating the radiological response to preoperative chemotherapy for 168 patients undergoing surgical therapy for colorectal liver metastases at Johns Hopkins Hospital between 2000 and 2008. Results: Forty patients (23. 8%) had one or more DLM, accounting for a total of 127 lesions. In 22 patients (55%), all DLM sites were treated during surgery. Of the 17 patients with unidentified, untreated DLM, ten patients (59%) developed a local recurrence at the initial site, half of which also developed recurrences in other sites. While the intrahepatic recurrence rate was higher for patients with DLM left in situ (p = 0.04), the 1-, 3-, and 5-year overall survival rate was not significantly different for patients with DLM left in situ (93.8%, 63.5%, and 63.5%, respectively) when compared to patients with a radiological chemotherapy response in whom all original disease sites were surgically treated (92.3%, 70.8%, and 46.2%, respectively; p = 0.66). Conclusions: DLM were frequently observed in patients undergoing preoperative chemotherapy for liver metastases. Survival was comparable in patients with untreated DLM, in spite of high intrahepatic recurrence rates seen in these patients. Therefore, aggressive surgical therapy should be considered in patients with marked response to chemotherapy, even when all DLM sites cannot be identified.

AB - Background: With increasing efficacy of preoperative chemotherapy for colorectal cancer, more patients will present with one or more disappearing liver metastases (DLM) on preoperative cross-sectional imaging. Patients and Methods: A retrospective review was conducted evaluating the radiological response to preoperative chemotherapy for 168 patients undergoing surgical therapy for colorectal liver metastases at Johns Hopkins Hospital between 2000 and 2008. Results: Forty patients (23. 8%) had one or more DLM, accounting for a total of 127 lesions. In 22 patients (55%), all DLM sites were treated during surgery. Of the 17 patients with unidentified, untreated DLM, ten patients (59%) developed a local recurrence at the initial site, half of which also developed recurrences in other sites. While the intrahepatic recurrence rate was higher for patients with DLM left in situ (p = 0.04), the 1-, 3-, and 5-year overall survival rate was not significantly different for patients with DLM left in situ (93.8%, 63.5%, and 63.5%, respectively) when compared to patients with a radiological chemotherapy response in whom all original disease sites were surgically treated (92.3%, 70.8%, and 46.2%, respectively; p = 0.66). Conclusions: DLM were frequently observed in patients undergoing preoperative chemotherapy for liver metastases. Survival was comparable in patients with untreated DLM, in spite of high intrahepatic recurrence rates seen in these patients. Therefore, aggressive surgical therapy should be considered in patients with marked response to chemotherapy, even when all DLM sites cannot be identified.

KW - Chemotherapy

KW - Colorectal liver metastases

KW - Liver resection

UR - http://www.scopus.com/inward/record.url?scp=77958496525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958496525&partnerID=8YFLogxK

U2 - 10.1007/s11605-010-1348-y

DO - 10.1007/s11605-010-1348-y

M3 - Article

C2 - 20839072

AN - SCOPUS:77958496525

VL - 14

SP - 1691

EP - 1700

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 11

ER -